About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 983 record(s)
Req # A-2023-000827
Additional details for Natural Health Product (NHP) Site License 300694 (Medline Canada Corporation). If Medline Canada Corporation: is a MANUFACTURER, LABELLER, PACKAGER, or IMPORTER or if it serves as storage/warehouse only. Has listed any FOREIGN…Organization: Health Canada
January 2024
Req # A-2023-000849
All correspondence related to the Estradiol Abbreviated New Drug Submission (ANDS).Organization: Health Canada
January 2024
Req # A-2023-000879
The Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs establishment licence Good Manufacturing Practices (GMP) inspection of the Apotex facility (Site A) on Signet Drive, Toronto,…Organization: Health Canada
January 2024
Req # A-2023-000916
The Abbreviated New Drug Submission (ANDS) no. 262177 filed by JAMP Pharma Corporation for nintedanib or nintedanib esilate, copies of any Notice of Deficiency (NOD), Notice of Non-Compliance (NON), NOD-Withdrawal (NOD-W), or NON-Withdrawal (NON-W…Organization: Health Canada
January 2024
Req # A-2023-000918
Abbreviated New Drug Submission (ANDS) no. 262177 filed by JAMP for nintedanib or nintedanib esilate, copies of any response by JAMP to any Notice of Deficiency (NOD), Notice of Non-Compliance (NON), NOD-Withdrawal (NOD-W), or NON-Withdrawal (NON-W).Organization: Health Canada
January 2024
Req # A-2023-000968
Information on the intended use of a device listed on Medical Device Active License Listing (MDALL). Requesting it for the following: Licence No.: 95942, Type: System, Device class: 2, Device first issue date 2015-10-15, Licence name: VIASURE,…Organization: Health Canada
January 2024
Req # A-2023-000970
Briefing notes, emails, meeting appointments, or minutes involving, addressed to or received by the Minister or the Deputy Minister at Health Canada and their Offices from the Public Health Agency of Canada, and correspondence sent or addressed to…Organization: Health Canada
January 2024
Req # A-2023-001022
The Certified Product Information Document (CPID) submitted for the Liraglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
January 2024
Req # A-2023-001023
The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Liraglutide ANDS.Organization: Health Canada
January 2024
Req # A-2023-001025
Any Screening Acceptance Letter sent by Health Canada to the sponsor of the Liraglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
January 2024